Bin Huang

Bin Huang

Auto-generated profile, based on publicly available information

Bin Huang

Division of Vascular Surgery, Department of General Surgery, West China Hospital, Sichuan University, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2022 in Trials
Verified
Journal Article
Open access
PDF file
YQYu-Han Qi
Yu-Han Qi
JWJiarong Wang
Jiarong Wang
JZJichun Zhao
Jichun Zhao
BHBing Huang
Bing Huang
FXFei Xiong
Fei Xiong
DYDing Yuan
Ding Yuan
Background: Covered stent has become one of the mainstream therapies for aortoiliac obstructive disease (AIOD), with a higher patency rate than bare metal stent. Covered balloon-expandable (CBE) stent can be placed more accurately with higher a radial support force, while covered self-expanding (CSE) stent has greater elasticity and higher trackability. However, there is no level I evidence regarding the comparison safety and efficacy between the CSE stent and CBE stent in AIOD to date. Therefore, this study aims to compare the efficacy and safety of CBE stent (BARD®LIFESTREAM™) and CSE stent (GORE® VIABAHN™) in AIOD. Methods: This trial is a prospective, single-center, parallel, noninferiority, randomized controlled trial. A total of 106 patients will be enrolled and these patients will be randomized to either the CBE stent group or the CSE stent group. The primary end point of the study is the occurrence of target lesion revascularization (TLR) at 12 months after the intervention. Discussion: To our knowledge, the ballooN sElf cOver steNt AorToiliAc occuLusive (NEONATAL) trial is the first RCT to compare CBE and CSE stent in AIOD patients. The main aim is to compare the TLR of the target lesion between CBE stent and CSE stent at 12 months post-procedure. The results of clinical trials may contribute to establishing a strategic guideline for choosing the optimal type of covered stent in the treatment of AIOD patients. Trial registration: Chinese Clinical Trials Registry ChiCTR2100046734. Registered on 27 May 2021

28 October 2026 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
LZLinyao Zhu
Linyao Zhu
YQYuhan Qi
Yuhan Qi
JWJiarong Wang
Jiarong Wang
CWChengxin Weng
Chengxin Weng
HHHankui Hu
Hankui Hu
JZJichun Zhao
Jichun Zhao
Objective: Emergent or urgent repair of thoracoabdominal aortic aneurysms (TAAA) always represent a major challenge due to high mortality and complex reconstruction of visceral arteries. We aimed to evaluate the short- and long-term outcomes of patients undergoing emergent or urgent hybrid TAAA repair under a standardized institutional perioperative protocol. Methods: This study represents a retrospective cohort analysis of data derived from a prospectively maintained institutional database at West China Hospital. All consecutive patients who underwent emergent or urgent hybrid repair for TAAA between January 2013 and February 2025 were included. Results: The cohort comprised 38 TAAA patients (31 male, with a median age of 50.5 years) who underwent emergent/urgent hybrid repair. The median aneurysm length was 200.9 mm (IQR 154.0-320.0), with a mean maximum diameter was 70.5 ± 17.8 mm. Intraoperatively, 4 visceral arteries (IQR 4-5) were reconstructed. Median operative time was 415 min (IQR 360-504), with median ICU and postoperative hospital stays of 96.0 h (IQR 46.5-203.5) and 17 days (IQR 11-24), respectively. No myocardial infarction or hepatic failure occurred. Postoperative complications included pulmonary infection ( n = 4, 10.5%), acute kidney injury ( n = 2, 5.3%), and spinal cord ischemia ( n = 5, 13.2%). Thirty-day mortality was 10.5% ( n = 4). The survival rates at 12 and 60 months postoperatively were 86.8% (95% CI 76.7–98.3) and 83.0% (95% CI 71.7–96.6). The free of reintervention rates at 12 and 60 months postoperatively were 90.5% (95% CI 80.8–100.0) and 76.4% (95% CI 61.1–95.7). Conclusion: In this selected cohort managed with a standardized perioperative protocol, emergent and urgent hybrid TAAA repair was feasible, with acceptable perioperative mortality and durable mid- to long-term survival. However, the occurrence of spinal cord ischemia represents a substantial and clinically significant trade-off of this approach in the emergency setting. Moreover, these favorable survival outcomes should be interpreted in the context of the cohort's relatively young age and favorable baseline risk profile. These findings emphasize that survival benefit is counterbalanced by significant neurological morbidity, highlighting the need for refined spinal protection protocols in urgent cases and for comparative studies to validate the specific efficacy of this standardized protocol.